Logo 400x400.jpg
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
August 01, 2023 16:15 ET | CytoSorbents
Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points...
Logo 1200x628.jpg
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
July 26, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents New Logo - 2021.png
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
July 19, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents New Logo - 2021.png
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
July 11, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents New Logo - 2021.png
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
July 07, 2023 07:07 ET | CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents New Logo - 2021.png
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
June 15, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents New Logo - 2021.png
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
June 05, 2023 09:00 ET | CytoSorbents
PRINCETON, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents New Logo - 2021.png
CytoSorbents Reports First Quarter 2023 Results
May 02, 2023 16:15 ET | CytoSorbents
PRINCETON, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents New Logo - 2021.png
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
April 26, 2023 07:00 ET | CytoSorbents
MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents New Logo - 2021.png
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
April 19, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...